Palisade Capital Management’s Heron Therapeutics HRTX Stock Holding History

Palisade Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.91M	Sell	6,140,639 -185,474	-3%	-$215K	0.16%	151
2025 Q4	$8.22M	Sell	6,326,113 -1,001,334	-14%	-$1.24M	0.24%	115
2025 Q3	$9.23M	Buy	7,327,447 +2,240,544	+44%	+$3.55M	0.25%	113
2025 Q2	$10.5M	Sell	5,086,903 -200,028	-4%	-$408K	0.3%	104
2025 Q1	$11.6M	Buy	5,286,931 +1,360,542	+35%	+$2.64M	0.33%	99
2024 Q4	$6.01M	Sell	3,926,389 -65,889	-2%	-$107K	0.16%	154
2024 Q3	$7.94M	Sell	3,992,278 -56,850	-1%	-$136K	0.21%	127
2024 Q2	$14.2M	Buy	4,049,128 +316,887	+8%	+$974K	0.39%	87
2024 Q1	$10.3M	Buy	3,732,241 +86,138	+2%	+$217K	0.27%	109
2023 Q4	$6.2M	Sell	3,646,103 -464,848	-11%	-$512K	0.16%	147
2023 Q3	$4.23M	Sell	4,110,951 -32,698	-0.8%	-$46.5K	0.12%	170
2023 Q2	$4.81M	Buy	4,143,649 +173,363	+4%	+$309K	0.13%	165
2023 Q1	$6M	Buy	3,970,286 +184,391	+5%	+$462K	0.16%	153
2022 Q4	$9.46M	Buy	3,785,895 +397,263	+12%	+$1.28M	0.25%	120
2022 Q3	$14.3M	Buy	3,388,632 +424,558	+14%	+$1.66M	0.41%	82
2022 Q2	$8.27M	Buy	2,964,074 +42,967	+1%	+$173K	0.22%	130
2022 Q1	$16.7M	Sell	2,921,107 -113,065	-4%	-$827K	0.38%	91
2021 Q4	$27.7M	Buy	3,034,172 +542,589	+22%	+$5.54M	0.56%	60
2021 Q3	$26.6M	Buy	2,491,583 +672,452	+37%	+$8.19M	0.58%	55
2021 Q2	$28.2M	Buy	1,819,131 +755,397	+71%	+$12M	0.64%	53
2021 Q1	$17.2M	Buy	1,063,734 +173,116	+19%	+$3.09M	0.41%	91
2020 Q4	$18.9M	Buy	890,618 +70,079	+9%	+$1.22M	0.48%	72
2020 Q3	$12.2M	Buy	820,539 +145,174	+21%	+$2.27M	0.37%	99
2020 Q2	$9.94M	Buy	675,365 +5,127	+0.8%	+$84.2K	0.32%	108
2020 Q1	$7.87M	Buy	670,238 +75,040	+13%	+$1.41M	0.29%	121
2019 Q4	$14M	Buy	595,198 +54,379	+10%	+$1.2M	0.4%	89
2019 Q3	$10M	Buy	540,819 +33,398	+7%	+$615K	0.31%	105
2019 Q2	$9.43M	Buy	507,421 +122,680	+32%	+$2.45M	0.29%	111
2019 Q1	$9.4M	Buy	384,741 +81,135	+27%	+$2.12M	0.31%	109
2018 Q4	$7.88M	Buy	+303,606	New	+$8.35M	0.29%	123

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.29B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CPC

Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return